ORCID Profile
0000-0002-6562-0230
Current Organisations
University of Hamburg
,
Bernhard-Nocht-Institut für Tropenmedizin
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 07-2020
DOI: 10.1016/J.TMAID.2020.101557
Abstract: Lassa Fever (LF), is a severe viral disease prevalent in Western Africa. It is classified as a priority disease by the World Health Organization (WHO). Ribavirin is the recommended therapy despite weak evidence of its efficacy. Promising therapeutic agents are becoming available for evaluation in human. Before launching therapeutic trials, we need data on the evolution of the disease under the best possible conditions of care. We have initiated a prospective study in Nigeria to better understand the clinical course and prognostic factors of LF while implementing high quality standardized care. Inclusion criteria are: suspected or confirmed LF and informed consent. Participants are followed 60 days from admission and receive free of charge standardized supportive care and biological monitoring, as well as intravenous ribavirin for those with confirmed LF. Data are collected using standardized case report forms (CRF). Primary and secondary outcomes are fatality and severe morbidity, with special focus on acute kidney dysfunction and pregnancy complications. Factors associated with outcomes will be investigated. The cohort is planned for 3 years. Inclusions started in April 2018 at the Federal Medical Center Owo in Ondo State. A second site will open in Nigeria in 2020 and discussions are underway to open a site in Benin. 150 to 200 new participants are expected per year. This cohort will: provide evidence to standardize LF case management provide key inputs to design future clinical trials of novel therapeutics and establish clinical research teams capable of conducting such trials in LF-endemic areas. The LASCOPE study was registered on ClinicalTrial.gov (NCT03655561).
Publisher: Springer Science and Business Media LLC
Date: 31-08-2021
Publisher: Springer Science and Business Media LLC
Date: 28-11-2022
DOI: 10.1007/S00705-022-05546-Z
Abstract: In March 2022, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by two new families (bunyaviral Discoviridae and Tulasviridae), 41 new genera, and 98 new species. Three hundred forty-nine species were renamed and/or moved. The accidentally misspelled names of seven species were corrected. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.
Publisher: Springer Science and Business Media LLC
Date: 17-11-2021
Publisher: Springer Science and Business Media LLC
Date: 04-09-2020
Publisher: Oxford University Press (OUP)
Date: 2016
DOI: 10.1093/VE/VEW016
Publisher: Elsevier BV
Date: 04-2021
Publisher: CSIRO Publishing
Date: 2015
DOI: 10.1071/AN14137
Abstract: Conventional shearing of sheep is labour-intensive, expensive and presents significant occupational health and safety risks. The only alternative at present is based on injection of epidermal growth factor, which severs the fibre at the follicle level. This technology cannot be used in pregnant animals and requires application of a net to retain the severed fleece. An alternative is to create a weakened zone within the wool staple, which would be sufficiently strong to retain the fleece on the sheep while a protective covering regrows, but sufficiently weak as to allow painless and automated removal of the fleece. We demonstrate that this approach is possible using mixtures of amino acids lacking lysine and methionine. Initially we demonstrate the relationships between staple strength, a subjective ‘harvestability’ score and a subjective ‘pain’ score, using fleeces from animals treated with varying levels of cortisol to create a wide range of strengths of wool attachment. We assigned a score to the ease with which we could manually break the staples, and also to the animal’s response to breaking the staples still attached to the skin. The relationships between these variables indicated that a staple was considered harvestable and could be removed with minimal skin flinch response at a staple strength of ~10–13 N/kTex. Staples within this range were then produced by intravenous infusion of mixtures of amino acids lacking in lysine and methionine for a 5-day period. The weak point was uniformly created across the entire fleece and when a prototype roller-pin device was applied to the weakened wool, it uniformly broke the fleece of the three sheep tested. The mode of action of the amino acid treatment on wool growth was studied. There was no effect of unbalanced amino acids on the rate of follicle bulb cell ision, the number of active wool follicles, or the length of the keratinisation zone in the wool follicle. Fibre diameter was reduced by ~4 microns by treatment, and intrinsic fibre strength (strength relative to cross-sectional area of the wool fibres), was reduced by ~50%. Results of these trials are encouraging but further work is required to develop a practical, on-farm method of altering systemic amino acid supply and to design an automated, high-throughput system of severing the weakened wool.
Publisher: Microbiology Society
Date: 25-08-2023
DOI: 10.1099/JGV.0.001864
Publisher: Springer Science and Business Media LLC
Date: 04-2017
DOI: 10.1038/NATURE22040
Location: Germany
No related grants have been discovered for Stephan Günther.